![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/calliditas-partner-everest-medicines-starts-commercial-launch-of-nefecon-in-china-302144848.html
https://www.prnewswire.com/news-releases/everest-medicines-announces-financial-results-for-full-year-ended-december-31-2023-302101804.html
https://www.biospectrumasia.com/news/25/23966/singapore-gives-nod-to-china-based-everest-medicines-drug-for-nephropathy-treatment.html
https://www.prnewswire.com/news-releases/everest-medicines-announces-singapore-health-sciences-authority-approves-nefegan-for-the-treatment-of-primary-iga-nephropathy-in-adult-patients-302093775.html
https://www.prnewswire.com/news-releases/everest-medicines-strengthens-management-team-with-appointments-of-chief-medical-officer-and-chief-product-officer-302090990.html
https://www.prnewswire.com/news-releases/everest-medicines-partner-calliditas-therapeutics-announces-us-fda-grants-an-additional-seven-year-orphan-drug-exclusivity-period-for-nefecon-302086016.html
https://www.prnewswire.com/news-releases/everest-medicines-announces-acceptance-of-velsipity-new-drug-application-in-macau-302084833.html
https://www.prnewswire.com/news-releases/everest-medicines-to-announce-full-year-2023-financial-results-on-march-28-2024-302080731.html
https://www.prnewswire.com/news-releases/everest-medicines-announces-termination-of-collaboration-agreements-with-providence-302064738.html